NASA astronauts Butch Wilmore and Suni Williams are steadily recovering after spending nine unexpected months aboard the International Space Station (ISS) due to issues with Boeing’s Starliner capsule. Initially intended for an eight-day test flight, the mission extended when Starliner experienced propulsion problems that forced NASA to return the capsule uncrewed in 2023.
The astronauts returned to Earth in March 2025 and have since undergone intensive physical therapy to readjust to gravity. Wilmore, 62, noted the difficulties of re-adapting to Earth's conditions, saying, “Gravity stinks for a period.” Williams, 59, echoed the challenges, highlighting muscle fatigue and delayed energy recovery. Both astronauts spent about two hours daily with NASA’s reconditioning specialists during a standard 45-day rehab period.
Despite lingering issues, such as neck pain for Wilmore and fatigue for Williams, both are now supporting Boeing and NASA operations, helping evaluate the Starliner program and contributing to ISS-related research. Wilmore noted that some of his preexisting physical pain vanished in microgravity but returned immediately upon splashdown.
Boeing has already incurred over $2 billion in costs developing Starliner and is awaiting a key decision from NASA: whether to mandate another uncrewed flight before resuming crewed missions. Williams supports the idea, citing the cautious approach taken by SpaceX and Russia in launching uncrewed missions before sending astronauts.
NASA expects to complete tests of Starliner over the summer, which will determine if it’s ready to fly humans again. Williams and Wilmore continue to be key figures in that assessment as Boeing aims to regain trust in its human spaceflight program.
The Starliner setback adds to Boeing’s ongoing challenges, contrasting with the consistent performance of rival capsules developed by SpaceX. NASA’s upcoming decision will be pivotal for Boeing’s future in space exploration.


Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Trump Says Anthropic No Longer Seen as National Security Threat
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions
SpaceX IPO Sparks Market Optimism as Shares Surge 19% on Trading Debut
Trump Administration Releases New UFO Files and Apollo Mission Records
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand
Tabletop particle accelerator could transform medicine and materials science
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples
China vs. NASA: The New Moon Race and What's at Stake by 2030
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions
Saudi Aramco Explores Sulphur Business Stake Sale to Raise Billions
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 



